SG11201906880VA - Engineered phenylalanine ammonia lyase polypeptides - Google Patents

Engineered phenylalanine ammonia lyase polypeptides

Info

Publication number
SG11201906880VA
SG11201906880VA SG11201906880VA SG11201906880VA SG11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA SG 11201906880V A SG11201906880V A SG 11201906880VA
Authority
SG
Singapore
Prior art keywords
pal
california
polypeptides
fessif
redwood city
Prior art date
Application number
SG11201906880VA
Inventor
Chinping Chng
William Hallows
Nicholas Agard
Oscar Alvizo
Nikki Dellas
Gjalt Huisman
John Nicols
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of SG11201906880VA publication Critical patent/SG11201906880VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

0 0 025 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIP0 1 PCT 0111111010 0111 °nolo olommoillin onovoimIE (10) International Publication Number WO 2018/148633 Al (51) International Patent Classification: A61K 38/51 (2006.01) A61P 3/00 (2006.01) A61K 45/00 (2006.01) A61P 43/00 (2006.01) (21) International Application Number: PCT/US2018/017773 (22) International Filing Date: 12 February 2018 (12.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/458,232 13 February 2017 (13.02.2017) US 62/565,555 29 September 2017 (29.09.2017) US (71) Applicant: CODEXIS, INC. [US/US]; 200 Penobscot Dri- ve, Redwood City, California 94063 (US). (72) Inventors: CHNG, Chinping; 200 Penobscot Drive, Red- wood City, California 94063 (US). HALLOWS, William, Casey; 200 Penobscot Drive, Redwood City, California 94063 (US). AGARD, Nicholas, J.; 1047 Diamond St., San Francisco, California 94114 (US). ALVIZO, Oscar; 200 Penobscot Drive, Redwood City, California 94063 (US). DELLAS, Nikki; 200 Penobscot Drive, Redwood City, California 94063 (US). HUISMAN, Gjalt, W.; 200 Penobscot Drive, Redwood City, California 94063 (US). NICOLS, John, Joseph; 200 Penobscot Drive, Redwood City, California 94063 (US). (74) Agent: MACKNIGHT, Kamrin, T.; Codexis, Inc., 200 Penobscot Drive, Redwood City, California 94063 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = (54) Title: ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES -4- Av PAL PBS - Av PAL FaSSIF -A- Av PAL FeSSIF Early -v- Av PAL FeSSIF Middle - Av PAL FeSSIF Late -o- Variant 126 PBS -o- Variant 126 FaSSIF - 6 - Variant 126 FeSSIF Early Variant 126 FeSSIF Middle - o- Variant 126 FeSSIF Late 0.00 0 2 4 6 8 10 15 20 25 30 Time (hrs) FIG. 1 (57) : The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engi- neered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes. C [Continued on next page] WO 2018/148633 Al MIDEDIMOMOIDEIREEMOMMIVE110110100MEMOIS OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201906880VA 2017-02-13 2018-02-12 Engineered phenylalanine ammonia lyase polypeptides SG11201906880VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458232P 2017-02-13 2017-02-13
US201762565555P 2017-09-29 2017-09-29
PCT/US2018/017773 WO2018148633A1 (en) 2017-02-13 2018-02-12 Engineered phenylalanine ammonia lyase polypeptides

Publications (1)

Publication Number Publication Date
SG11201906880VA true SG11201906880VA (en) 2019-08-27

Family

ID=63106144

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906880VA SG11201906880VA (en) 2017-02-13 2018-02-12 Engineered phenylalanine ammonia lyase polypeptides

Country Status (15)

Country Link
US (4) US10995329B2 (en)
EP (1) EP3579867A4 (en)
JP (2) JP2020505942A (en)
KR (1) KR102573324B1 (en)
CN (1) CN110573175A (en)
AU (1) AU2018217495B2 (en)
BR (1) BR112019016634A2 (en)
CA (1) CA3051262A1 (en)
IL (1) IL268226A (en)
MX (1) MX2019009615A (en)
MY (1) MY196740A (en)
NZ (1) NZ755628A (en)
PH (1) PH12019501705A1 (en)
SG (1) SG11201906880VA (en)
WO (1) WO2018148633A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. Engineered tyrosine ammonia lyase
CN112355034B (en) 2020-11-17 2021-08-06 同济大学 Organic solid waste harmless pretreatment method based on hydrothermal calcium ion blending
CN115518691B (en) * 2022-10-14 2023-11-21 天津大学 Artificial enzyme with laccase-like activity, and preparation method and application thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK75593D0 (en) 1993-06-25 1993-06-25 Novo Nordisk As
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
DK0765394T3 (en) 1994-06-03 2001-12-10 Novozymes As Purified Myceliopthora laccases and nucleic acids encoding them
EP0777737B1 (en) 1994-06-30 2005-05-04 Novozymes Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
FI104465B (en) 1995-06-14 2000-02-15 Valio Oy Protein hydrolyzates for the treatment and prevention of allergies and their preparation and use
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6265201B1 (en) 1997-01-17 2001-07-24 Regents Of The University Of Minnesota DNA molecules and protein displaying improved triazine compound degrading ability
JP4062366B2 (en) 1997-01-17 2008-03-19 マキシジェン，インコーポレイテッド Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1999029902A1 (en) 1997-12-08 1999-06-17 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
AU3221699A (en) 1998-04-02 1999-10-25 Tellus Genetic Resources, Inc. A method for obtaining a plant with a genetic lesion in a gene sequence
IL139093A0 (en) 1998-05-01 2001-11-25 Maxygen Inc Optimization of pest resistance genes using dna shuffling
US6337186B1 (en) 1998-06-17 2002-01-08 Maxygen, Inc. Method for producing polynucleotides with desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US6605430B1 (en) 1998-08-12 2003-08-12 Maxygen, Inc. DNA shuffling of monooxygenase genes for production of industrial chemicals
CA2345203A1 (en) 1998-10-07 2000-04-13 Maxygen Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
JP4221100B2 (en) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 Semiconductor device
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
AU3210100A (en) 1999-01-19 2000-08-01 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
KR20010102069A (en) 1999-02-11 2001-11-15 추후제출 High throughput mass spectrometry
CA2364997A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Encryption of traits using split gene sequences
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
CA2396320A1 (en) 2000-01-11 2001-07-19 Maxygen, Inc. Integrated systems and methods for diversity generation and screening
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
EP1287123B1 (en) 2000-04-03 2011-03-02 Maxygen, Inc. Subtilisin variant
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
SI2315145T1 (en) 2002-03-01 2016-03-31 Codexis Mayflower Holdings, Llc Methods, systems, and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US8003356B2 (en) 2004-04-20 2011-08-23 E. I. Du Pont De Nemours And Company Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8768871B2 (en) 2008-02-12 2014-07-01 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
EP3023494B1 (en) 2008-06-13 2018-11-28 Codexis, Inc. Method of synthesizing polynucleotide variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
PT3025728T (en) 2010-02-04 2018-11-05 Biomarin Pharm Inc Method for purifying prokaryotic phenylalanine ammonia-lyase variants
EP2635685A4 (en) 2010-11-05 2014-05-21 Basf Plant Science Co Gmbh Method for increasing yield and fine chemical production in plants
WO2012122333A1 (en) 2011-03-08 2012-09-13 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Microbial conversion of glucose to styrene and its derivatives
WO2012178126A1 (en) 2011-06-23 2012-12-27 Phytogene, Inc. Enzymatic system for monomer synthesis
DK2726651T3 (en) 2011-06-28 2019-01-28 Codexis Inc PROTEIN INVARIANT GENERATION BY REGION SHUFFLING
US20150050658A1 (en) 2012-03-15 2015-02-19 Codexix, Inc. Gene shuffling methods
KR20150113166A (en) 2013-01-31 2015-10-07 코덱시스, 인코포레이티드 Methods, systems, and software for identifying bio-molecules with interacting components
HUE043549T2 (en) * 2013-04-18 2019-08-28 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
AU2014324670B2 (en) 2013-09-27 2019-11-21 Codexis, Inc. Structure based predictive modeling
EP3418929B1 (en) 2013-09-27 2020-12-09 Codexis, Inc. Automated screening of enzyme variants
JP6702866B2 (en) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド Synthetic membrane-receiver complex

Also Published As

Publication number Publication date
MY196740A (en) 2023-05-03
EP3579867A4 (en) 2021-03-10
NZ755628A (en) 2023-09-29
PH12019501705A1 (en) 2020-07-06
CN110573175A (en) 2019-12-13
JP2022103296A (en) 2022-07-07
MX2019009615A (en) 2019-10-14
AU2018217495B2 (en) 2021-03-04
EP3579867A1 (en) 2019-12-18
US20230295598A1 (en) 2023-09-21
BR112019016634A2 (en) 2020-04-07
KR102573324B1 (en) 2023-08-30
US10995329B2 (en) 2021-05-04
AU2018217495A1 (en) 2019-08-08
US20210222145A1 (en) 2021-07-22
US20180230448A1 (en) 2018-08-16
WO2018148633A1 (en) 2018-08-16
JP2020505942A (en) 2020-02-27
IL268226A (en) 2019-09-26
KR20190117577A (en) 2019-10-16
CA3051262A1 (en) 2018-08-16
US20230295599A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201908391XA (en) Methods for modulating an immune response
SG11201909957TA (en) Engineered ligase variants
SG11201805645QA (en) Lsd1 inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201809064QA (en) Chimeric neurotoxins
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201408112XA (en) Random access and signaling of long-term reference pictures in video coding
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201906880VA (en) Engineered phenylalanine ammonia lyase polypeptides
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof